First patient treated in phase iib study of Naronapride in patients with gastroparesis
First patient treated in phase iib study of Naronapride in patients with gastroparesisFirst patient treated in phase iib study of Naronapride in patients with gastroparesis1
Dr Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both through our own internal teams, and also in collaboration with key external partners.
We're pleased to share the latest update in the attached press release on further progress of the clinical trial program for Naronapride, in patients with gastroparesis. This co-development with Renexxion Ireland Ltd, is a multi-centre, randomised, double blind, placebo controlled Phase Ilb trial evaluating the efficacy, safety and tolerability of Naronapride in patients with gastroparesis. The first patient has now been treated in Europe.
Reference: 1. Dr Falk Pharma. Press Release. Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis.